Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol in Malignant Melanoma Progression
NCT01988831Phase 2Suspended
- Start
- Jun 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of propranolol in melanoma (2 arms). Primary endpoint: Progression-Free Survival at 5 years. Started Jun 2016; status: suspended.
02
Drugs
propranolol
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01988831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01988831.